Immunological therapies targeting leukemia
Faculty of Medicine and Nutrition, University Juárez of Durango State, Durango, Dgo. Mexico.
Review Article
GSC Biological and Pharmaceutical Sciences, 2024, 29(02), 264–270.
Article DOI: 10.30574/gscbps.2024.29.2.0434
Publication history:
Received on 14 October 2024; revised on 21 November 2024; accepted on 23 November 2024
Abstract:
Leukemia represents one of the greatest challenges in medical oncology due to its aggressiveness and biological complexity. Immunotherapy has recently emerged as a promising option for the treatment of leukemias, however, its genetic complexity has represented a challenge for it. ALL and AML present different genetic alterations, such as mutations, chromosomal rearrangements and signaling pathways. Currently, several therapies have been investigated and applied to try to treat leukemia, among them, CAR T-cell therapy has shown great effectiveness, monoclonal antibodies are another promising option, several immune checkpoint inhibitors have also been developed, the use of CAR-NK cells offers another promising alternative, and as usual, stem cell transplantation remains an important curative option. Leukemia treatments continue to be renewed and updated to make them less toxic and less aggressive for patients.
Keywords:
Tumor microenvironment; CAR-T cells; Monoclonal antibodies; Biomarkers; Hematopoietic stem cells; Toxicity in immunotherapy.
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
